MENU
OCT 7 - 8 2020

Cancer Research & Oncology 2020

LabRoots and the Cancer Research and Oncology Planning Committee are pleased to announce the 8th Annual Cancer Research and Oncology Virtual Event! This two day event will take place on October 7th and 8th, 2020 and will focus on advancements in prevention, diagnosis and treatment of different cancer types.

Cancer research has made major advancements in diagnosis, treatments, and the basic understanding of the disease itself. Each year we see progress in immunotherapy, treatments involving nanotechnology, advances in targeted and personalized therapeutics and drug development, and a decrease in mortality rates due to a strong focus on learning more about the origination of the disease.

This year's event will include the following tracks:
  • The Role of Evolution in Drug and Radiation Resistance of Cancer - October 7th
  •  The latest in Immunotherapy and Other Novel Cancer Therapeutics - October 7th
  •  Health Disparities: How Cancer Impacts the Underrepresented and Underserved - October 8th
  •  Molecular/Genetic Guidance Versus Standard of Care - October 8th
  •  New Methods to Understand Cancer Biology - October 8th

Our virtual conference allows you to participate in a global setting with no travel or cost to you. The event will remain open 6 months from the date of the live event.  The webinars will be available for unlimited on-demand viewing.  This virtual conference also offers increased reach for the global microbiology community with a high degree of interaction through live-streaming video and chat sessions.

Like the 2019 conference, this event will be produced on our robust platform, allowing you to watch, learn and connect seamlessly across all desktop or mobile devices. Equipped with gamification and point system, you can now move around the entire event, earning points for a chance to win one of LabRoots' most popular T-shirts.



Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Plan now to have your poster included in the 2020 Cancer Research and Oncology Virtual Event. Submission is free. Submit your abstract here.

Continuing Education
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 35 credits.

Use #LRcancer to follow the conversation!


Speakers
  • Gynecologic Oncologist and Geneticist, Upstate Cancer Center, Cancer Genetics Program
  • PhD Student, Miltenyi Biotec
  • Associate Professor, Vice Chair for Diversity, Equity and Inclusion, Department of Population Health Sciences, Duke University School of Medicine, Associate Research Professor, Duke Global
  • Gilead Sciences, Foster City, CA Jan., 2011 - current Associate Scientist I (2011-2013), Biologics and Target Biology Associate Scientist II (2014-2015), Biomarker / Biology Core Support
  • Head of Portfolio Management and Product Development, Genome Engineering & Modulation
  • Professor of Urology and Epidemiology & Biostatistics, Associate Chair for Clinical Research, Dept of Urology, UCSF Helen Diller Family Comprehensive Cancer Center
  • Product Marketing Manager
  • Senior Scientist, Digital PCR Assay Development, QIAGEN GmbH
  • Senior Staff Scientist, Division of Cellular Signaling, Research Institute, National Cancer Center
  • Professor, Dept. of Biomedical and Biological Sciences, JLC Biomedical Biotechnology Research Institute, North Carolina Central University
  • Senior Research Investigator II, Leads Discovery & Optimization, Bristol Myers Squibb, Princeton, NJ, USA
  • Senior Vice President of Shanghai ChemPartner and is the head of the Biology and Pharmacology Department
  • Assistant Professor, Division of Medical Oncology, Huntsman Cancer Institute
  • Sr. Director, Development at Biodesix, Inc.
  • Medical Director, AdventHealth Global Robotics Institute, Medical Director, AdventHealth Cancer Institute Urologic Oncology Program, Professor of Urology, University of Central Florida
  • Deputy Director, Duke Cancer Institute, Professor of Medicine, Professor of Pharmacology and Cancer Biology, Professor of Family Medicine and Community Health, Duke University Medical Center
  • Director, Robotic Surgery, Providence St. Joseph Health Care System and Swedish Medical Center
  • CEO, Cellphenomics
  • Professor of Cancer Immunotherapy, Nottingham Trent University, United Kingdom
  • Director, R&D, QIAGEN
  • Head of Antibody Development
  • Assistant Attending Physician-Scientist, Memorial Sloan Kettering Cancer Center
  • Associate Director, PreAnalytiX R&D, QIAGEN

Show Resources
You May Also Like
NOV 11, 2021 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
NOV 11, 2021 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Twelveyears ago LabRoots launched a new system of learning for a global scientific audience. Now, the 2021 Clinical Diagnostics and Research Virtual Event will again bring together clinician...
SEP 07, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
SEP 07, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is excited to bring academia and industry, research experts, virologists, microbiologists, healthcare professionals, and leading biomedical scientists under one roof at our 7 th Ann...
APR 20, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
APR 20, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is excited to announce our 9th Annual Genetics Virtual Week held on April 20-22, 2021! Genetics Virtual Week 2021 will offer a multi-day content-rich program combining stellar exper...
FEB 10, 2021 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
FEB 10, 2021 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is pleased to announce the 10th annual Laboratory Animal Science (LAS) Virtual Conference which will take place on February 10th 2021. This is the premier on...
JUN 02, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
JUN 02, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is pleased to announce the inauguration of the Immuno-Oncology Virtual Event taking place on June 2, 2021. Immuno-oncology is considered by some to be one of the most promising area...
OCT 06, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
OCT 06, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots and the Cancer Research and Oncology Planning Committee are pleased to announce the 9th Annual Cancer Research and Oncology Virtual Event! This two day event will take place on Octo...
Agenda
  • High-throughput biomarker profiling in immuno-oncology research & development
    OCT 08, 2020 6:00 PM PDT
    High-throughput biomarker profiling in immuno-oncology research & development
    Jenny Koenitzer, PhD
    Senior Research Investigator II, Leads Discovery & Optimization, Bristol Myers Squibb, Princeton, NJ, USA
    Sponsored By: MilliporeSigma
  • Multimodal analysis of circulating cell-free RNA (ccfRNA), cell-free DNA (ccfDNA), genomic DNA (gDNA) and CTCs from blood samples in cancer research
    OCT 08, 2020 6:00 PM PDT
    Multimodal analysis of circulating cell-free RNA (ccfRNA), cell-free DNA (ccfDNA), genomic DNA (gDNA) and CTCs from blood samples in cancer research
    Thorsten Voss, PhD
    Associate Director, PreAnalytiX R&D, QIAGEN
    Sponsored By: QIAGEN
  • Multiplex detection of oncogenic mutations using LNA-based assays on the QIAcuity digital PCR system
    OCT 08, 2020 4:30 PM PDT
    Multiplex detection of oncogenic mutations using LNA-based assays on the QIAcuity digital PCR system
    Dr. Özlem Karalay
    Senior Scientist, Digital PCR Assay Development, QIAGEN GmbH
    Sponsored By: QIAGEN
  • Reducing biological variance in tumor-antigen expression to standardize potency testing for immunotherapies
    OCT 08, 2020 3:00 PM PDT
    Reducing biological variance in tumor-antigen expression to standardize potency testing for immunotherapies
    Benjamin Borgo, PhD
    Head of Portfolio Management and Product Development, Genome Engineering & Modulation
    Sponsored By: MilliporeSigma
  • Nucleic acid preparation - DNA, RNA and retrieving both from the same FFPE sample
    OCT 08, 2020 1:30 PM PDT
    Nucleic acid preparation - DNA, RNA and retrieving both from the same FFPE sample
    Martin Schlumpberger, PhD
    Associate Director, Scientific Applications, Sample Technologies Development, Qiagen GmbH
    Sponsored By: QIAGEN
  • ZooMAb® Antibodies- a Novel Recombinant Antibody Technology
    OCT 08, 2020 12:00 PM PDT
    ZooMAb® Antibodies- a Novel Recombinant Antibody Technology
    Wayne Speckmann, PhD
    Head of Antibody Development
    Sponsored By: MilliporeSigma
  • Keynote Presentation: Principles of Effective Method Development in Pathobiology Research.
    OCT 08, 2020 10:30 AM PDT
    Keynote Presentation: Principles of Effective Method Development in Pathobiology Research.
    Vivian Barry, MS
    Gilead Sciences, Foster City, CA Jan., 2011 - current Associate Scientist I (2011-2013), Biologics and Target Biology Associate Scientist II (2014-2015), Biomarker / Biology Core Support
    Sponsored By: Roche Diagnostics
  • Blood-based detection of EGFR and KRAS mutations for NSCLC patients using multiplexed droplet digital PCR
    OCT 08, 2020 9:00 AM PDT
    Blood-based detection of EGFR and KRAS mutations for NSCLC patients using multiplexed droplet digital PCR
    Hestia Mellert, PhD
    Sr. Director, Development at Biodesix, Inc.
    Sponsored By: Bio-Rad Laboratories
  • Keynote Presentation: RNA Splicing and Ancestry-related Molecular Targets in Precision Oncology and Cancer Disparities
    OCT 08, 2020 7:30 AM PDT
    Keynote Presentation: RNA Splicing and Ancestry-related Molecular Targets in Precision Oncology and Cancer Disparities
    Steven R. Patierno, PhD
    Deputy Director, Duke Cancer Institute, Professor of Medicine, Professor of Pharmacology and Cancer Biology, Professor of Family Medicine and Community Health, Duke University Medical Center
  • Looking for Evidence-Based Oncology? T̶r̶y̶ Do Targeted Proteomics!
    OCT 08, 2020 6:00 AM PDT
    Looking for Evidence-Based Oncology? T̶r̶y̶ Do Targeted Proteomics!
    Christian Regenbrecht, PhD
    CEO, Cellphenomics
    Sponsored By: LUMINEX
  • Getting Under the Hood of Racial Disparities in Prostate Cancer
    Getting Under the Hood of Racial Disparities in Prostate Cancer
    Matthew R. Cooperberg, MD
    Professor of Urology and Epidemiology & Biostatistics, Associate Chair for Clinical Research, Dept of Urology, UCSF Helen Diller Family Comprehensive Cancer Center
  • Hereditary Cancer Genetics
    Hereditary Cancer Genetics
    Rinki Agarwal, MD FACOG,FACMG
    Gynecologic Oncologist and Geneticist, Upstate Cancer Center, Cancer Genetics Program
  • The biology of cancer disparities: an innate immunity story
    The biology of cancer disparities: an innate immunity story
    K. Sean Kimbro, PhD
    Professor, Dept. of Biomedical and Biological Sciences, JLC Biomedical Biotechnology Research Institute, North Carolina Central University
  • Transcriptome analysis of breast cancer clinical specimens with long-read sequencer
    Transcriptome analysis of breast cancer clinical specimens with long-read sequencer
    Masahito Kawazu, MD
    Senior Staff Scientist, Division of Cellular Signaling, Research Institute, National Cancer Center
  • We Don't Care What You Know Until You Show Us That You Care': Characterizing Access to Healthcare among Black, Hispanic and White Cancer Survivors
    We Don't Care What You Know Until You Show Us That You Care': Characterizing Access to Healthcare among Black, Hispanic and White Cancer Survivors
    Tomi Akinyemiju, PhD, MS
    Associate Professor, Vice Chair for Diversity, Equity and Inclusion, Department of Population Health Sciences, Duke University School of Medicine, Associate Research Professor, Duke Global
  • Artificial Intelligence in Digital Pathology
    OCT 07, 2020 1:30 PM PDT
    Artificial Intelligence in Digital Pathology
    Branden Hopkinson, PhD
    Product Marketing Manager
    Sponsored By: Visiopharm®
  • Drugging the Undruggable Cancer Targets
    OCT 07, 2020 12:00 PM PDT
    Drugging the Undruggable Cancer Targets
    Dr. Ming Liu
    Senior Vice President of Shanghai ChemPartner and is the head of the Biology and Pharmacology Department
    Sponsored By: ChemPartner
  • Immune correlates of TP53 mutational status in acute myeloid leukemia
    OCT 07, 2020 10:30 AM PDT
    Immune correlates of TP53 mutational status in acute myeloid leukemia
    Dr. Sergio Rutella
    Professor of Cancer Immunotherapy, Nottingham Trent University, United Kingdom
    Sponsored By: NanoString Technologies
  • Keynote Presentation: Retroperitoneal Robotic Partial Nephrectomy for Renal Cell Carcinoma
    OCT 07, 2020 9:00 AM PDT
    Keynote Presentation: Retroperitoneal Robotic Partial Nephrectomy for Renal Cell Carcinoma
    Dr. James Porter
    Director, Robotic Surgery, Providence St. Joseph Health Care System and Swedish Medical Center
  • How to derive and expand primary tumor cell cultures
    OCT 07, 2020 7:30 AM PDT
    How to derive and expand primary tumor cell cultures
    David J. Agorku
    PhD Student, Miltenyi Biotec
    Sponsored By: Miltenyi Biotec
  • Keynote Presentation: Robotic Radical Prostatectomy:  Lessons learned from 14,000 cases
    OCT 07, 2020 6:00 AM PDT
    Keynote Presentation: Robotic Radical Prostatectomy: Lessons learned from 14,000 cases
    Vipul Patel, MD
    Medical Director, AdventHealth Global Robotics Institute, Medical Director, AdventHealth Cancer Institute Urologic Oncology Program, Professor of Urology, University of Central Florida
  • Immunotherapy in Prostate and Renal Cell Carcinoma: Panoply of Futuristic Therapies
    Immunotherapy in Prostate and Renal Cell Carcinoma: Panoply of Futuristic Therapies
    Benjamin Maughan, MD, PharmD
    Assistant Professor, Division of Medical Oncology, Huntsman Cancer Institute
  • Oncogene additivity in the PI3K pathway in cancer
    Oncogene additivity in the PI3K pathway in cancer
    Neil Vasan, MD, PhD
    Assistant Attending Physician-Scientist, Memorial Sloan Kettering Cancer Center
  • The latest in Immunotherapy and Other Novel Cancer Therapeutics
  • Immunotherapy in Prostate and Renal Cell Carcinoma: Panoply of Futuristic Therapies
    Immunotherapy in Prostate and Renal Cell Carcinoma: Panoply of Futuristic Therapies
    Benjamin Maughan, MD, PharmD
    Assistant Professor, Division of Medical Oncology, Huntsman Cancer Institute
  • Keynote Presentation: Robotic Radical Prostatectomy:  Lessons learned from 14,000 cases
    OCT 07, 2020 6:00 AM PDT
    Keynote Presentation: Robotic Radical Prostatectomy: Lessons learned from 14,000 cases
    Vipul Patel, MD
    Medical Director, AdventHealth Global Robotics Institute, Medical Director, AdventHealth Cancer Institute Urologic Oncology Program, Professor of Urology, University of Central Florida
  • How to derive and expand primary tumor cell cultures
    OCT 07, 2020 7:30 AM PDT
    How to derive and expand primary tumor cell cultures
    David J. Agorku
    PhD Student, Miltenyi Biotec
    Sponsored By: Miltenyi Biotec
  • Keynote Presentation: Retroperitoneal Robotic Partial Nephrectomy for Renal Cell Carcinoma
    OCT 07, 2020 9:00 AM PDT
    Keynote Presentation: Retroperitoneal Robotic Partial Nephrectomy for Renal Cell Carcinoma
    Dr. James Porter
    Director, Robotic Surgery, Providence St. Joseph Health Care System and Swedish Medical Center
  • Immune correlates of TP53 mutational status in acute myeloid leukemia
    OCT 07, 2020 10:30 AM PDT
    Immune correlates of TP53 mutational status in acute myeloid leukemia
    Dr. Sergio Rutella
    Professor of Cancer Immunotherapy, Nottingham Trent University, United Kingdom
    Sponsored By: NanoString Technologies
  • Drugging the Undruggable Cancer Targets
    OCT 07, 2020 12:00 PM PDT
    Drugging the Undruggable Cancer Targets
    Dr. Ming Liu
    Senior Vice President of Shanghai ChemPartner and is the head of the Biology and Pharmacology Department
    Sponsored By: ChemPartner
  • Artificial Intelligence in Digital Pathology
    OCT 07, 2020 1:30 PM PDT
    Artificial Intelligence in Digital Pathology
    Branden Hopkinson, PhD
    Product Marketing Manager
    Sponsored By: Visiopharm®
  • Health Disparities: How Cancer Impacts the Underrepresented and Underserved
  • The biology of cancer disparities: an innate immunity story
    The biology of cancer disparities: an innate immunity story
    K. Sean Kimbro, PhD
    Professor, Dept. of Biomedical and Biological Sciences, JLC Biomedical Biotechnology Research Institute, North Carolina Central University
  • Getting Under the Hood of Racial Disparities in Prostate Cancer
    Getting Under the Hood of Racial Disparities in Prostate Cancer
    Matthew R. Cooperberg, MD
    Professor of Urology and Epidemiology & Biostatistics, Associate Chair for Clinical Research, Dept of Urology, UCSF Helen Diller Family Comprehensive Cancer Center
  • Looking for Evidence-Based Oncology? T̶r̶y̶ Do Targeted Proteomics!
    OCT 08, 2020 6:00 AM PDT
    Looking for Evidence-Based Oncology? T̶r̶y̶ Do Targeted Proteomics!
    Christian Regenbrecht, PhD
    CEO, Cellphenomics
    Sponsored By: LUMINEX
  • Keynote Presentation: RNA Splicing and Ancestry-related Molecular Targets in Precision Oncology and Cancer Disparities
    OCT 08, 2020 7:30 AM PDT
    Keynote Presentation: RNA Splicing and Ancestry-related Molecular Targets in Precision Oncology and Cancer Disparities
    Steven R. Patierno, PhD
    Deputy Director, Duke Cancer Institute, Professor of Medicine, Professor of Pharmacology and Cancer Biology, Professor of Family Medicine and Community Health, Duke University Medical Center
  • Molecular/Genetic Guidance Versus Standard of Care
  • Hereditary Cancer Genetics
    Hereditary Cancer Genetics
    Rinki Agarwal, MD FACOG,FACMG
    Gynecologic Oncologist and Geneticist, Upstate Cancer Center, Cancer Genetics Program
  • Blood-based detection of EGFR and KRAS mutations for NSCLC patients using multiplexed droplet digital PCR
    OCT 08, 2020 9:00 AM PDT
    Blood-based detection of EGFR and KRAS mutations for NSCLC patients using multiplexed droplet digital PCR
    Hestia Mellert, PhD
    Sr. Director, Development at Biodesix, Inc.
    Sponsored By: Bio-Rad Laboratories
  • New Methods to Understand Cancer Biology
  • Keynote Presentation: Principles of Effective Method Development in Pathobiology Research.
    OCT 08, 2020 10:30 AM PDT
    Keynote Presentation: Principles of Effective Method Development in Pathobiology Research.
    Vivian Barry, MS
    Gilead Sciences, Foster City, CA Jan., 2011 - current Associate Scientist I (2011-2013), Biologics and Target Biology Associate Scientist II (2014-2015), Biomarker / Biology Core Support
    Sponsored By: Roche Diagnostics
  • ZooMAb® Antibodies- a Novel Recombinant Antibody Technology
    OCT 08, 2020 12:00 PM PDT
    ZooMAb® Antibodies- a Novel Recombinant Antibody Technology
    Wayne Speckmann, PhD
    Head of Antibody Development
    Sponsored By: MilliporeSigma
  • Nucleic acid preparation - DNA, RNA and retrieving both from the same FFPE sample
    OCT 08, 2020 1:30 PM PDT
    Nucleic acid preparation - DNA, RNA and retrieving both from the same FFPE sample
    Martin Schlumpberger, PhD
    Associate Director, Scientific Applications, Sample Technologies Development, Qiagen GmbH
    Sponsored By: QIAGEN
  • Reducing biological variance in tumor-antigen expression to standardize potency testing for immunotherapies
    OCT 08, 2020 3:00 PM PDT
    Reducing biological variance in tumor-antigen expression to standardize potency testing for immunotherapies
    Benjamin Borgo, PhD
    Head of Portfolio Management and Product Development, Genome Engineering & Modulation
    Sponsored By: MilliporeSigma
  • Multiplex detection of oncogenic mutations using LNA-based assays on the QIAcuity digital PCR system
    OCT 08, 2020 4:30 PM PDT
    Multiplex detection of oncogenic mutations using LNA-based assays on the QIAcuity digital PCR system
    Dr. Özlem Karalay
    Senior Scientist, Digital PCR Assay Development, QIAGEN GmbH
    Sponsored By: QIAGEN
  • High-throughput biomarker profiling in immuno-oncology research & development
    OCT 08, 2020 6:00 PM PDT
    High-throughput biomarker profiling in immuno-oncology research & development
    Jenny Koenitzer, PhD
    Senior Research Investigator II, Leads Discovery & Optimization, Bristol Myers Squibb, Princeton, NJ, USA
    Sponsored By: MilliporeSigma
  • Multimodal analysis of circulating cell-free RNA (ccfRNA), cell-free DNA (ccfDNA), genomic DNA (gDNA) and CTCs from blood samples in cancer research
    OCT 08, 2020 6:00 PM PDT
    Multimodal analysis of circulating cell-free RNA (ccfRNA), cell-free DNA (ccfDNA), genomic DNA (gDNA) and CTCs from blood samples in cancer research
    Thorsten Voss, PhD
    Associate Director, PreAnalytiX R&D, QIAGEN
    Sponsored By: QIAGEN
Posters

POSTER SUBMISSION GUIDELINES

Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer-reviewed. Submission is free.


SUBMIT YOUR ABSTRACT

Enter the following information to this Submission Form:

  • Poster Title
  • Your Name
  • Your Institution
  • Your Email
  • Abstract describing the poster


All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.

If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster. LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.

Questions? Email Posters@LabRoots.com

LabRoots Policy

Speakers

  • Rinki Agarwal, MD FACOG,FACMG
    Gynecologic Oncologist and Geneticist, Upstate Cancer Center, Cancer Genetics Program
    Biography

      I am a practicing Gynecologic Oncologist and Geneticist. I lead the Cancer Genetics Program at the Upstate Cancer Center in Syracuse, NY. In addition to this, I am actively involved in medical education and clinical research in Oncology. In my free time, I like to read books, movies, hiking and eating out.

    • David J. Agorku
      PhD Student, Miltenyi Biotec
      Biography

        David began his career at Miltenyi Biotec over ten years ago as a R&D laboratory technician. The ambitious student continued his education throughout his time at Miltenyi – first earning a Bachelors degree in Molecular Biology from Johannes Gutenberg University Mainz, then earning a Masters degree in the Life Sciences from HAN University of Applied Sciences in the Netherlands. Presently, David is continuing his studies as a PhD student while simultaneously remaining a valued member of Miltenyi’s R&D team, developing innovative solutions for cancer research.

      • Tomi Akinyemiju, PhD, MS
        Associate Professor, Vice Chair for Diversity, Equity and Inclusion, Department of Population Health Sciences, Duke University School of Medicine, Associate Research Professor, Duke Global
        Biography

          Dr. Akinyemiju is an Associate Professor of Epidemiology with expertise in cancer epidemiology, cancer biology, epidemiologic methods, and health disparities.  Her research interests include quantifying the impact of social (e.g. access to healthcare and structural racism) and biological factors (e.g. metabolic and inflammatory dysregulation) on racial disparities in cancer risk, tumor aggressiveness, quality of treatment and survival. This line of inquiry has resulted in over 100 publications till date. Dr. Akinyemiju is the PI of an NIH funded study examining the role of metabolic dysregulation and associated epigenetic changes in risk of aggressive, hormone-receptor negative breast cancer in women of African descent, and an R01 characterizing racial differences in various healthcare access dimensions, and how these predict poor treatment utilization and lower survival among Black, Hispanic and White ovarian cancer patients. These ultimate goal of these studies is to provide novel, empirical and generalizable insights that can help identify and prioritize specific modifiable factors that can be targeted to reduce cancer disparities and improve care for all patients, findings that will likely be beneficial across a range of cancer types where racial disparities remain an intractable problem.

        • Vivian Barry, MS
          Gilead Sciences, Foster City, CA Jan., 2011 - current Associate Scientist I (2011-2013), Biologics and Target Biology Associate Scientist II (2014-2015), Biomarker / Biology Core Support
          Biography

            Vivian Barry is a Senior Scientist in the Pathobiology group at Gilead Sciences.  She began her career in molecular biology and immunology research areas at DNAX and Genentech.  She eventually ventured into histopathology research and became the manager of the immunohistochemistry team at Arresto Biosciences in 2008.  Vivian joined Gilead in 2011, with the acquisition of Arresto, and has been managing the IHC/Pathology group at Gilead since that time.  Over the years, she has focused on building the histopathology lab and has introduced various machinery and techniques to enhance the delivery of high quality IHC and CISH data.  Her team focuses on target validation in both human tissues and animal models, assists in determining mechanism of action of therapeutics and small molecules, and is involved in IND-enabling studies.  She collaborates with investigators across Gilead’s departments; these projects include virology, immunology, oncology, and fibrotic diseases.  Vivian received her Bachelor of Science and Master of Science degrees at the University of San Francisco, and has recently received her MBA from the Golden Gate University, San Francisco.

          • Benjamin Borgo, PhD
            Head of Portfolio Management and Product Development, Genome Engineering & Modulation
            Biography

              Ben currently leads a team of forward-thinking product and service managers within MilliporeSigma's Genome Engineering and Modulation franchise. His first exposure to CRISPR-based genome editing was as a graduate student where he attempted to engineer novel protein variants. This work inspired a passion for CRISPR technology which he has brought with him to his current role within a company that is laser-focused on developing and utilizing revolutionary genome editing technologies. Prior to joining Merck KGaA, he has worked in various commercial and technical roles at Berkeley Light Inc., Agilent Technologies, Nanopore Diagnostics, and several small start-up companies focused on software applications. Ben has a PhD in computational biology from Washington University in St. Louis.

            • Matthew R. Cooperberg, MD
              Professor of Urology and Epidemiology & Biostatistics, Associate Chair for Clinical Research, Dept of Urology, UCSF Helen Diller Family Comprehensive Cancer Center
              Biography

                Matthew Cooperberg graduated from Dartmouth College, where he finished summa cum laude with a major in English. He earned his MD and MPH degrees at Yale University, and completed residency in Urology and fellowship in Urologic Oncology at UCSF. At the end of his training, Dr. Cooperberg joined the faculty at UCSF. He is Chief of Urology at the San Francisco VA Medical Center, and he maintains busy clinical practices both there and at the UCSF Helen Diller Family Comprehensive Cancer Center, where is the Urology co-Leader of the Prostate Program. He also holds a secondary appointment in the Department of Epidemiology & Biostatistics. He is actively engaged in research approaching the challenges of prostate cancer from many interrelated angles, from molecular analyses to health system-wide research. He has written or contributed to over 370 research articles. Early in 2013 Dr. Cooperberg co-authored a proposal for a national urology registry which served as the basis for the AUA Quality (AQUA) Registry, a project for which he now serves as Senior Physician Advisor. In 2015 he won the AUA Gold Cystoscope Award, and in 2016 was awarded his first R01 grant as Principle Investigator from the National Cancer Institute, to develop and validate novel miRNA-based biomarker signatures for refined prostate cancer prognosis. He lives in San Francisco with his wife, Jacqueline Dolev (a derm-atologist and fellow Yale Medical School alum), where they work primarily to keep up with their children, Jake and Sarah.

              • Branden Hopkinson, PhD
                Product Marketing Manager
                Biography

                  Branden Hopkinson has a PhD in Cellular and Genetic Medicine from the University of Copenhagen as well as a background in human embryonic stem cells and identification of cell origin for the various types of breast cancer. He also has extensive experience in the exploration of biomarkers for cell identification and diagnostic purposes.

                • Dr. Özlem Karalay
                  Senior Scientist, Digital PCR Assay Development, QIAGEN GmbH
                  Biography

                    Dr. Özlem Karalay, Senior Scientist, Digital PCR Assay Development, QIAGEN GmbH Özlem Karalay studied Molecular Biology & Genetics at the Middle East Technical University, Turkey, and obtained her M.Sc. degree in Neuroscience from the MPI for Developmental Biology, Tübingen. She received her doctorate in Neuroscience from the Swiss Federal Institute of Technology (ETH), Zürich. She joined QIAGEN after completion of her postdoctoral research at the MPI for Biology of Ageing, Cologne, and since then has been involved in developing the digital PCR assay portfolio, including mutation detection and CNV assays.

                  • Masahito Kawazu, MD
                    Senior Staff Scientist, Division of Cellular Signaling, Research Institute, National Cancer Center
                    Biography

                      Masahito Kawazu began his medical research after studying medicine at the University of Tokyo and being trained as a hematologist. After earning a degree in research on transcription factors and conducting research on transcriptional regulators as a postdoctoral fellow, he joined  Department of Cellular Signaling, The University of Tokyo, in 2010 and started his research on genomic medicine. His research focuses on genomic abnormalities of cancer cells. He aims to find genomic abnormalities that drive the growth of cancer or that affect the immune environment of cancer. He performed a genome analysis of breast cancer and microsatellite instability-high colorectal cancer, and clarified the characteristics of their genomic abnormality. Recently, his team is trying to analyze the abnormal transcripts resulting from the structural variations (chromosomal rearrangement) of cancer genome using a long-read sequencer.

                    • K. Sean Kimbro, PhD
                      Professor, Dept. of Biomedical and Biological Sciences, JLC Biomedical Biotechnology Research Institute, North Carolina Central University
                      Biography

                        Dr. Kimbro is a biomedical scientist, educator, and community researcher. With a career-spanning nearly thirty years in a wide variety of institutions across this country, Dr. Kimbro has continued to pursue excellence in the classroom and at the bench. He currently serves as a Professor of Biological and Biomedical Science at North Carolina Central University (NCCU) where his research focus involves the innate immune response pathway in cancer development and risk in African American populations. He returned to full-time research after serving as the Director of the Julius L. Chambers Biomedical/Biotechnology Research Institute (Institute). Dr. Kimbro’s cancer disparities expertise is widely recognized as evidenced by serving as a peer-reviewer of grants for the National Institutes of Health and his multiple peer-reviewed publications in health disparities. Dr. Kimbro is passionate about developing the next generation of investigators and has consistently been regarded as a favorite among graduate and undergraduate students alike. He is deeply committed to his community and has exercised considerable leadership in the area of health disparities. Prior to joining NCCU, Dr. Kimbro served as the Program Director of the Georgia Center for Health Equality at the Emory University School of Medicine, Winship Cancer Institute, a NIH Center of Excellence (COE). In his role at the Institute, Sean was instrumental in managing a variety of programs and initiatives to identify and address health disparities, particularly in the African-American community. Dr. Kimbro holds a B.A. in Biology from Washington University in St. Louis and a Ph.D. in Biological Sciences, with an emphasis in Molecular and Microbiology from Indiana University. He completed post-doctoral positions at Harvard University Medical School and the National Institutes of Health, National Institute of Environmental Health Sciences at Research Triangle Park, North Carolina.

                      • Jenny Koenitzer, PhD
                        Senior Research Investigator II, Leads Discovery & Optimization, Bristol Myers Squibb, Princeton, NJ, USA
                        Biography
                          Dr. Koenitzer is an immunobiologist in R&D at Bristol Myers Squibb in Princeton, NJ. During her time at BMS, she has focused on small molecule and biologics drug discovery in the immuno-oncology space.
                        • Dr. Ming Liu
                          Senior Vice President of Shanghai ChemPartner and is the head of the Biology and Pharmacology Department
                          Biography

                            Dr. Ming Liu is a Senior Vice President of Shanghai ChemPartner and is the head of the Biology and Pharmacology Department. Dr. Liu has more than 25 years of experience in drug discovery and development, with a focus on pre-clinical evaluations of novel therapeutic agents. Dr. Liu obtained his Ph.D. of Molecular Virology from Baylor College of Medicine in Houston, Texas. He received his postdoctoral training at the Dana Farber Cancer Institute at Harvard Medical School in Boston, Massachusetts. He worked for Schering-Plough and Merck Pharmaceuticals for nearly 20 years, focusing on cancer drug discovery and development. Additionally, Dr. Liu is a licensed veterinarian in Taiwan and the United States. He has published 40 peer review articles, 10 patents, and 4 book chapters.

                          • Benjamin Maughan, MD, PharmD
                            Assistant Professor, Division of Medical Oncology, Huntsman Cancer Institute
                            Biography

                              Benjamin Maughan MD, PharmD is an Assistant Professor in the Division of Medical Oncology at Huntsman Cancer Institute specializing in genitourinary malignancies. Dr. Maughan completed his PharmD, cum laude, from Idaho State University in 2004, then completed an oncology pharmacy residency at Mountain States Tumor Institute in 2005. Dr. Maughan earned his MD, cum laude, from the University of Kentucky, College of Medicine in 2010. He finished his Internal Medicine residency training with the University of Utah in 2013 and subsequently completed his medical oncology fellowship at Johns Hopkins in 2016. He has been awarded the Huntsman Cancer Institute Translational Scholar Award in 2019, and was selected for the 2019 SWOG Young Investigator Training Course. Dr. Maughan has clinical and research interests in all genitourinary oncology, with a particular focus on the development of novel therapeutics and in identification of predictive biomarkers. During fellowship he studied predictive biomarkers in metastatic prostate cancer, specifically the role of truncated androgen receptors (AR-V7 expression) and loss of tumor suppressors (PTEN and Rb). More recently he is studying predictive biomarkers to immune therapy combinations in kidney, bladder and prostate cancers. He is exploring novel immune therapy combinations including checkpoint inhibitors combined with radiation therapy (radium-223), oncolytic viruses (MVA-brachyury) and targeted therapies (such as cabozantinib).

                            • Hestia Mellert, PhD
                              Sr. Director, Development at Biodesix, Inc.
                              Biography

                                Dr. Mellert is a Senior Director within the Biodesix development group.  She has a background in molecular cancer biology and experience leading teams in the development and commercialization of blood-based, and now respiratory based, diagnostic tests under CAP/CLIA and NYS CLEP.  Dr. Mellert has played a leading role in the launch and on-market support of the GeneStrat tests which uses ddPCR technology. Most recently she has contributed to the expanded use of this platform at Biodesix to support molecular testing for SARS-CoV-2 infection.  She continues to focus her efforts on bringing relevant and actionable genomic and proteomic information into the Clinical Laboratory to support pharmaceutical development programs and physicians. Dr. Mellert received her Ph.D from the University of Pennsylvania and post-doctoral training at the University of Colorado.  She has received several honors including the American Cancer Society Post-doctoral fellowship and inaugural Biodesix Invent Our Future award.

                              • Vipul Patel, MD
                                Medical Director, AdventHealth Global Robotics Institute, Medical Director, AdventHealth Cancer Institute Urologic Oncology Program, Professor of Urology, University of Central Florida
                                Biography

                                  Vipul Patel, MD, FACS completed his medical school education at Baylor College of Medicine in Houston, TX.  He then completed his residency and fellowship training at the University of Miami in Florida.  Subsequently, Dr. Patel served as director of the Robotic Surgery Program at The Ohio State University in Columbus, Ohio, prior to joining Advent Health Celebration. Dr. Patel is board certified by the American Urological Association and is the medical director of the Global Robotics Institute at Advent Health Celebration and medical director of the Advent Health Cancer Institute Urologic Oncology Program.  He is a professor of Urology at the University of Central Florida College of Medicine in Orlando, Florida, and a clinical associate professor of Urology at Nova Southeastern University, also in Orlando. He serves as an honorary professor at the University of Milan, Korea University and Ricardo Palma University in Lima, Peru, and was recently made an honorary professor of the Russian Academy of Science. He is the founder of the International Prostate Cancer Foundation (IPCF) and a founding member of the Society of Robotic Surgery.  He is the editor emeritus of The Journal of Robotic Surgery and editor of the first-ever robotic urology textbook. He leads one of the world’s most experienced robotic surgery teams and travels around the world to educate physicians and care for patients. Dr. Patel is world-renowned for his contribution to the field of robotic surgery and prostate cancer. Dr Patel is the most experienced robotic surgeon in the world and has personally performed nearly 14,000 robotic prostatectomies for the treatment of prostate cancer. Dr. Patel has developed techniques in robotic surgery that have translated to improve patient care and outcomes. His innovations have helped to improve cancer treatment and return of early urinary continence and sexual function. His contributions have been recognized worldwide through publications, professorships and training courses. He has traveled the globe lecturing and teaching. He has educated thousands of surgeons in robotic surgical techniques. He has started robotic surgery programs or performed surgery throughout the United States and in countries, including India, China, England, Sweden, Belgium, Turkey, Australia and South Korea. He currently serves as president of the Florida Urologic Society and Past president and Managing Director of the Society of Robotic Surgery.

                                • Steven R. Patierno, PhD
                                  Deputy Director, Duke Cancer Institute, Professor of Medicine, Professor of Pharmacology and Cancer Biology, Professor of Family Medicine and Community Health, Duke University Medical Center
                                  Biography

                                    Steven R. Patierno, PhD serves as Professor of Medicine, Professor of Pharmacology and Cancer Biology and Professor of Family Medicine and Community Health at the Duke University School Medicine, and as Deputy Director of the Duke Cancer Institute (DCI), one of the original eight NCI-designated Comprehensive Cancer Centers. He earned a Bachelor of Science in Pharmacy from the University of Connecticut, a PhD in molecular pharmacology from the Graduate School of Biomedical Science, University of Texas Health Science Center-MD Anderson Cancer Institute in Houston Texas, and conducted an NIH-awarded postdoctoral fellowship at the University of Southern California (USC) Norris Comprehensive Cancer Center in molecular oncology and carcinogenesis. He was the Vivian Gill Distinguished Professor of Oncology, and Professor of Pharmacology, Physiology and Urology at the GWU School of Medicine and Health Sciences, and served as Executive Director of The George Washington University Cancer Center for ten years prior to moving to Duke in 2012. Dr. Patierno’s basic science and translational research laboratory has been funded continuously by the NIH, NCI, Department of Defense and multiple foundations for over 25 years. He is internationally recognized for research on molecular carcinogenesis, molecular pharmacology and oncology, the genomics of cancer disparities and healthcare delivery research on patient navigation and evidence-based policy. Currently, his laboratory is focused on the molecular biology of cancer disparities including the development of biomarkers for high risk cancer and identification and development of novel molecularly targeted therapeutics.  He serves on many national committees for AACR, AACI, and ASCO, and as chair of numerous scientific and medical advisory boards.  He co-chaired the 2007, and keynoted the 2018 AACR-NCI Think Tanks on Cancer Disparities and help found the AACR Science of Cancer Disparities Annual Conference. Dr. Patierno received a Prostate Cancer Foundation 2018 Challenge Award, the AACR 2019 Distinguished Cancer Disparities Research Award, and has been recognized as a Distinguished Alumnus of the University of Texas MD Anderson Cancer Institute.  He has also been recognized by Duke University for his extensive work in Diversity and Inclusion and by numerous organizations for impactful community engagement.

                                  • Dr. James Porter
                                    Director, Robotic Surgery, Providence St. Joseph Health Care System and Swedish Medical Center
                                    Biography

                                      Dr. James Porter is Director of Robotic Surgery at Providence St. Joseph Health Care System and Swedish Medical Center in Seattle, Washington.  He is former Associate Professor of Urology and head of laparoscopy and robotics in the Department of Urology at the University of Washington Medical Center.  He performed the first laparoscopic radical prostatectomy in the Pacific Northwest on October, 2000.  His area of expertise is robotic assisted prostatectomy, and partial nephrectomy.   He developed the retroperitoneal approach for robotic renal surgery and pioneered retroperitoneal lymph node dissection for the treatment of testicular cancer.  He has been director of a fellowship in robotic and laparoscopic surgery for the last 18 years.  He is the most experienced laparoscopic and robotic surgeon in the Pacific Northwest and has performed over 4,000 robotic procedures.   He earned his undergraduate degree in biochemistry at Ohio State University.  He received his medical degree from the Medical College of Ohio and performed his urology residency at the University of Washington Medical Center.  He obtained advanced laparoscopic training in Heilbronn, Germany under the direction of Dr. Jens Rassweiler.

                                    • Christian Regenbrecht, PhD
                                      CEO, Cellphenomics
                                      Biography
                                        Christian has studied biology and philosophy at the University of Bonn. In 2005 he did his first postdoc with Hans Lehrach at the Max Planck Institute for Molecular Genomics in Berlin. In 2010 his group moved to the Institute for Pathology at the Charité - Universitätsmedizin Berlin focussing on improved patient-derived in vitro models. During his time at the Charité he was appointed head of the core-facility for functional genomics of the Charité. Within the IMI initiative Oncotrack Christian was the the academic lead of the work package in vitro models & cancer stem cells. In 2012 he, together with SAP was awarded with the Innovation award of the states Berlin and Brandenburg for his work on the Oncolyzer, a mobile-device app that allows to analyze clinical records of cancer-patients in real-time. Since May 2017 he is speaker and member of the advisory committee for Berlin's "Pharma Solutions" ZIM cluster. Christian is member of distinguished national and international scientific societies, including the New York Academy of Sciences (NYAS), the American Association for Cancer Research (AACR), the European Association for Cancer Research (EACR), the Connective Tissue Oncology Society (ctos),the German Cancer Society (DKG) and Berlin's Cancer Society (BKG).
                                      • Dr. Sergio Rutella
                                        Professor of Cancer Immunotherapy, Nottingham Trent University, United Kingdom
                                        Biography

                                          Professor Rutella is a licensed haematologist and Professor of Cancer Immunotherapy at the John van Geest Cancer Research Centre. His academic career has been predicated on the bench-to-bedside-to-bench paradigm in Haematology. Over the last 25 years, Professor Rutella has been engaged in clinical and translational research focusing on immunotherapy approaches to improve the outcome of haematological malignancies, with an emphasis on antibody-based therapeutics and haematopoietic stem cell transplantation. At Nottingham Trent University, Professor Rutella’s research program focuses on visualising the state of cancer-immune interactions in individual patients and on biomarker discovery, with the aim to design rational immunotherapy approaches and to guide treatment choices.

                                        • Martin Schlumpberger, PhD
                                          Director, R&D, QIAGEN
                                          Biography

                                            Martin Schlumpberger is Director, Product Development at QIAGEN focusing on exosomes and circulating, cell-free nucleic acid isolation. Before his current role, he successfully led the development of various RNA isolation products at QIAGEN, including RNeasy FFPE, RNeasy Plus, AllPrep DNA/RNA, miRNeasy and QIAsymphony RNA kits. Prior to joining QIAGEN, Martin worked as a postdoctoral fellow at the Institute for Neurodegenerative Diseases at UCSF, USA. He holds a Ph.D. in chemistry, with a strong focus on molecular biology and yeast genetics, from the University of Stuttgart, Germany.

                                          • Wayne Speckmann, PhD
                                            Head of Antibody Development
                                            Biography

                                              Dr. Wayne Speckmann has been working in R&D for over 20 years and is an expert in antibody development and immunoassays.

                                            • Neil Vasan, MD, PhD
                                              Assistant Attending Physician-Scientist, Memorial Sloan Kettering Cancer Center
                                              Biography

                                                Neil Vasan is an Assistant Attending Physician on the Breast Medicine Service at Memorial Sloan Kettering Cancer Center. He is a physician-scientist working in the laboratory of Dr. Lewis Cantley (Weill Cornell Medical College) on oncogenic kinases and mechanisms of response to targeted therapies, with a focus on breast cancer. His work has been published in Nature and Science. He has received the NIH/NCI K08 Award, the Susan G. Komen Career Catalyst Research Award, the ASCO Young Investigator Award, and was named a 2020 AACR NextGen Star.

                                              • Thorsten Voss, PhD
                                                Associate Director, PreAnalytiX R&D, QIAGEN
                                                Biography

                                                  Scientific Career:

                                                  • Studied biology at University of Münster, Germany
                                                  • Ph.D. in molecular genetics and microbiology
                                                  • Postdoc at IBWF in Kaiserslautern, Germany

                                                  Professional Career

                                                  • Scientist at Artemis Pharmaceuticals Cologne
                                                  • Since 2004 at QIAGEN
                                                  • Associate Director R&D, PreAnalytiX
                                                  • Developed PAXgene collection and nucleic acid isolation products
                                                Sponsored by

                                                For information on becoming a sponsor or exhibitor, please click here.


                                                C.E. Credits

                                                The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


                                                Committee

                                                To download the Program Committee brochure here.


                                                • David Albala

                                                  Dr. David M. Albala graduated with a geology degree from Lafayette College in Easton, Pennsylvania. He completed his medical school training at Michigan State University and went on to complete his surgical residency at the Dartmouth-Hitchcock Medical Center. Following this, Dr ...

                                                  See more See less
                                                • Antonio Baines

                                                  Dr. Antonio T. Baines is an Associate Professor in the Department of Biology at North Carolina Central University (NCCU) and an adjunct professor in the Department of Pharmacology in the School of Medicine at the University of North Carolina (UNC) Chapel Hill. He earned a ...

                                                  See more See less
                                                • Rajan Gupta

                                                  Dr. Rajan T. Gupta, MD, is an Assistant Professor of Radiology in the Division of Abdominal Imaging at Duke University Medical Center, as well as the Director of the Abdominal Imaging Fellowship Program and a Faculty physician in the Duke Cancer Institute. Since 2009, he has been ...

                                                  See more See less
                                                • Keith Knutson

                                                  Keith L. Knutson, Ph.D., is a consultant in the Department of Immunology, Mayo Clinic in Florida, where he also serves as director of the Discovery and Translation Lab's Cancer Research Program. Dr. Knutson joined the staff of Mayo Clinic in 2005 and holds the academic rank of ...

                                                  See more See less
                                                • Jonas Korlach

                                                  Jonas Korlach was appointed Chief Scientific Officer of Pacific Biosciences in July 2012. He was previously a Scientific Fellow, supporting commercial development of the PacBio RS II system and performing research aimed at developing new applications for SMRT technologies. He ...

                                                  See more See less
                                                • Khyati Shah

                                                  Khyati Shah received her Ph.D. in Molecular Pharmacology from the University of the Pacific, Stockton, California. Her graduate research was completed in the lab of Jesika Faridi, Ph.D. Her work focused on the investigation of the mechanism of Akt induced tamoxifen resistance in ...

                                                  See more See less
                                                Help

                                                General LabRoots Questions

                                                email support@labroots.com  

                                                Virtual Events and Webinars

                                                Supported Configurations

                                                • Operating System Internet Explorer Firefox Chrome Safari
                                                  Vista IE8+ FF10+ Chrome15+
                                                  Windows 7 IE8+ FF10+ Chrome15+
                                                  Windows 8 IE10 FF10+ Chrome15+
                                                  Mac OS X   FF10+ Chrome15+ Safari5.1+
                                                • Cookie settings: session cookies enabled
                                                • Browser configuration must have JavaScript enabled
                                                • Adobe Flash player 10.2 or later

                                                To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                                Internet Connection

                                                • A minimum of 100Kbps is recommended for audio-only events
                                                • A minimum of 300Kbps is recommended for speaker on-video events

                                                Computer Equipment

                                                • Screen Resolution: Minimum 1024x768
                                                • Video Card: 65,000 colors minimum
                                                • Sound card and speakers (or headphones) for hearing webcast in full format
                                                • Audio Card: 16-bit minimum
                                                • RAM: 512MB of free RAM

                                                Firewall Protocol

                                                • HTTP on port 80 or HTTPS on port 443
                                                • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                                • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                                Work-At-Home Attendees

                                                • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                                For A Seamless Experience

                                                When using a mobile device, FREE Mobile Apps are available:

                                                - For viewing Webinars:

                                                - For viewing Virtual Events

                                                Attendee Guide

                                                • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                                Virtual Event and Webinar Support:

                                                Continuing Education (CME/CE) Support

                                                Loading Comments...
                                                Show Resources
                                                Attendees
                                                • See more